"Promising Cancer Vaccine Advances to Phase 3 Trials"

Dr. Thomas Wagner's tumor lysate particle only (TLPO) cancer vaccine, which uses a person's tumor cells to stimulate the immune system to fight cancer, has shown promising results in Phase 2 clinical trials, with nearly 95% of patients still alive three years after starting treatment and 64% disease-free. The U.S. FDA has approved the vaccine for a Phase 3 trial, aiming to enroll 500 people and set to launch this year. The vaccine's success in treating advanced melanoma has sparked hope for a potential cure for all cancers, if paired with early detection, and has been personally impactful for the president of Orbis Health Solutions, whose father lived 10 more years after receiving the vaccine for lung cancer.